Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based Therapies Offer Strong Potential in Difficult-To-Treat Subtypes

Description:

Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibiting distinct underlying etiologies and patho-physiologies. While technological advances and extensive research efforts have furthered the understanding of the pathophysiology of these complex indications, substantial gaps in scientific knowledge remain.

Pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action. Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena.

The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. It is identified that 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.

Global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products' efficacy in treating moderate to severe acute pain. Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

The report “Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes” provides a brief analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape.

In depth, it provides the following:

- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Helps to identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.

Contents:

1 Table of Contents
2 Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Options
4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Current Unmet Needs

5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class and Established Pipeline Products by Pain Subtype
5.5 Table of All First-in-Class Pain Pipeline Products

6 Pain Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Central Nervous System
6.2 Matrix Assessment

7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16
7.3 Pipeline Programs Targeting Bradykinin B1 Receptor
7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor
7.5 Pipeline Programs Targeting Purinoceptor 7
7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7
7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer

List of Tables
Table 1: Pain Market, Global, Categories of Pain, 2016
Table 2: Pain Market, Global, Data for Nerve Growth Factor as a Molecular Target, 2016
Table 3: Pain Market, Global, Data for High Affinity Nerve Growth Factor Receptor as a Molecular Target, 2016
Table 4: Pain Market, Global, Data for Tumor Necrosis Factor Receptor Superfamily Member 16 as a Molecular Target, 2016
Table 5: Pain Market, Global, Data for Bradykinin B1 Receptor as a Molecular Target, 2016
Table 6: Pain Market, Global, Data for Opioid Receptor-Like-1 Receptor as a Molecular Target, 2016
Table 7: Pain Market, Global, Data for Purinoceptor 7 as a Molecular Target, 2016
Table 8: Pain Market, Global, Data for Metabotropic Glutamate Receptor 6 as a Molecular Target, 2016
Table 9: Pain Market, Global, Data for Metabotropic Glutamate Receptor 7 as a Molecular Target, 2016
Table 10: Pain Market, Global, Data for Calcitonin Gene-Related Peptide Type-1 Receptor as a Molecular Target, 2016
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based Therapies Offer Strong Potential in Difficult-To-Treat Subtypes
Web Address: http://www.researchandmarkets.com/reports/3843310/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

| Electronic (PDF) - Single User: |  | USD 6995 |
| Electronic (PDF) - Site License: |  | USD 13990 |
| Electronic (PDF) - Enterprisewide: |  | USD 20985 |

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof  
First Name:  ___________________________  Last Name:  ___________________________
Email Address:  *  
Job Title:  
Organisation:  
Address:  
City:  
Postal / Zip Code:  
Country:  
Phone Number:  
Fax Number:  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World